Mantova

Researchers are evaluating the effectiveness and safety of a combination treatment called triple therapy, which includes bempedoic acid, ezetimibe, and either atorvastatin or rosuvastatin. This study focuses on patients with primary hypercholesterolemia or mixed dyslipidemia who are at high or very high cardiovascular risk. The goal is to understand how well this combination lowers LDL cholesterol (LDL-C) in a real-world clinical setting. The study observes patients who have already started triple therapy within the last four weeks. No drugs are administered as part of this study; instead, it monitors the ongoing treatment with bempedoic acid combined with ezetimibe and either rosuvastatin or atorvastatin. The study measures LDL-C changes from baseline to eight weeks after starting triple therapy and continues follow-up for one year to assess lipid goal achievement, adherence to therapy, treatment changes, laboratory value shifts, and occurrence of cardiovascular events. Participants will have their LDL-C levels and other lab values assessed at baseline, eight weeks, and one year after starting triple therapy. Researchers will collect data on adverse events, adherence to treatment, and cardiovascular outcomes such as heart attack, stroke, death from cardiovascular causes, and coronary procedures during the follow-up year. The study also tracks treatment pathways and changes over this period to better understand real-world use and effectiveness of this triple therapy approach.

Researchers are investigating patients affected by aneurysmal subarachnoid hemorrhage (aSAH), a type of hemorrhagic stroke caused by the rupture of a brain aneurysm, leading to bleeding in the space around the brain. Although early treatment has improved survival, many patients still develop long-term disabling neurological problems. The study focuses on delayed ischemic neurological deficit (DIND), a condition that can lead to delayed cerebral ischemia (DCI) and worsened neurological outcomes. There is no established standard for diagnosing or treating DIND, and the trial aims to describe its incidence, diagnostic imaging findings, and different treatment approaches across centers. The study observes patients with aSAH who require intensive care admission. Early aneurysm repair within 24 to 72 hours is standard, using techniques like endovascular coiling or surgical clipping. The trial collects data on clinical neurological exams and instrumental monitoring such as EEG and ultrasound to identify DIND. Various treatments for DIND are evaluated, including blood pressure management, intra-arterial vasodilator drugs, and mechanical angioplasty. The study also considers innovative methods like stent retriever angioplasty. No specific interventions are assigned by the study; it compares existing diagnostic and therapeutic strategies used in different centers. Participants undergo neurological assessments, brain imaging, and continuous monitoring to detect DIND and evaluate neurological outcomes over time. Researchers collect data on mortality and functional status in the short and long term, as well as treatment intensity and usefulness. The primary measure is the incidence of DIND within 12 months. The total duration of participation depends on patient follow-up. This comprehensive monitoring helps understand how different approaches impact patient recovery and complications after aSAH.

Researchers are investigating the evolution of neoadjuvant treatment for early breast cancer, focusing on patients with HER2-positive and Triple Negative tumors. The study aims to determine the percentage of these patients who received neoadjuvant therapy over the past five years, regardless of molecular subtype. Secondary goals include analyzing treatment choices, tumor characteristics, radiological responses, surgical procedures, adjuvant therapies, eligibility criteria changes, pathological complete response, disease-free survival, and overall survival according to molecular subtype and initial staging. This retrospective multicenter study reviews clinical practices in Italian oncology centers from 2016 to 2021. It includes patients diagnosed with early-stage breast cancer (stages I-III) who underwent neoadjuvant treatment. The study collects data on tumor subtype, treatment regimens, imaging methods such as breast MRI, ultrasound, mammography, and surgical treatments to understand therapeutic approaches and outcomes. Participants undergo data collection from medical records regarding tumor pathology, treatment responses, and survival outcomes over five years. Researchers measure the percentage of HER2-positive and Triple Negative tumors treated neoadjuvantly and perform descriptive analyses on treatment patterns and clinical features. The study also evaluates disease-free and overall survival related to pathological response and tumor subtype, providing insights into real-world treatment effectiveness and outcomes in early breast cancer.

The PREgnancy and FERtility (PREFER) study is a comprehensive program designed to improve care and knowledge about fertility preservation and pregnancy issues in young women with breast cancer. It includes two separate studies: PREFER-FERTILITY, which focuses on fertility preservation strategies and their outcomes, and PREFER-PREGNANCY, which investigates pregnancy management and outcomes for breast cancer patients diagnosed during or after pregnancy. This program is conducted across multiple Italian institutions and aims to collect detailed data to better understand these important topics. PREFER-FERTILITY collects information on patients' preferences and choices regarding fertility preservation options available in Italy, as well as the success and safety of these methods, such as ovarian function recovery and post-treatment pregnancies. PREFER-PREGNANCY gathers data on the treatment of breast cancer diagnosed during pregnancy, obstetrical and pediatric care for children exposed to anticancer treatments in utero, and clinical outcomes for breast cancer survivors who become pregnant after treatment. Both studies together provide a broad view of fertility and pregnancy challenges in this patient population. Participants are monitored for up to 15 years, with outcomes including rates of interest and uptake of fertility preservation strategies, types of strategies offered by oncologists, reasons for refusal, types of anticancer therapies during pregnancy, pregnancy complications, adverse events, disease-free survival, and overall survival. Data collection includes long-term follow-up to assess safety and effectiveness, aiming to optimize future care for young breast cancer patients facing fertility and pregnancy decisions.

Spontaneous coronary artery dissection (SCAD) is a cause of acute coronary syndromes that mainly affects young women without typical risk factors for atherosclerosis. Recent advances in understanding SCAD have come from regional and national registries, but there is a need for international collaboration to better understand diagnosis, treatment, and outcomes. This study aims to create the first pan-European SCAD registry to improve knowledge, guide clinical practice, and support research. This is an observational, multicenter, international retrospective and prospective cohort study involving at least 500 patients recruited prospectively and 500 historical cases. Data will be collected from patients diagnosed with SCAD within the past 10 years, including information from the first SCAD event and yearly follow-ups up to 5 years after enrollment. Approximately 30 countries and 120 sites will participate, and no treatments or interventions will be given as part of the study. Participants will have their medical records and coronary angiographic images reviewed at baseline and will be followed annually for up to 5 years. Information collected will include patient status, vital signs, recurrent SCAD events, imaging results, medications, menstrual and obstetric history, and discharge details. The study aims to gather comprehensive data to better understand SCAD management and long-term outcomes.